Erdanib is identified on this website as a product containing erdafitinib in stated 4 mg and 5 mg strengths. Product-specific manufacturer and regulatory information require verification.
Erdafitinib is an oral FGFR tyrosine kinase inhibitor used in selected patients with advanced urothelial carcinoma containing susceptible FGFR3 genetic alterations.
Current U.S. labeling covers adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy.
Yes. Current U.S. labeling requires selection of patients based on susceptible FGFR3 genetic alterations detected using an FDA-approved companion diagnostic.
FGFR3 is a fibroblast growth factor receptor that participates in cellular signaling. Certain genetic alterations can produce abnormal signaling associated with urothelial cancer.
Erdafitinib inhibits FGFR signaling, interfering with pathways that can support growth and survival of susceptible tumor cells.
Current U.S. BALVERSA labeling identifies 3 mg, 4 mg and 5 mg film-coated tablets.
The supplied product information identifies Erdanib in 4 mg and 5 mg strengths. Product-specific verification is required.
The current U.S. BALVERSA regimen is once daily.
Yes. Current U.S. labeling permits BALVERSA to be taken with or without food.
The current U.S. starting dose is 8 mg once daily. Appropriate patients may increase to 9 mg once daily after 14–21 days based on tolerability and phosphate levels.
The missed dose can be taken as soon as possible on the same day. The regular dose schedule resumes the next day, without taking extra tablets.
Yes. Ocular toxicity, including retinal pigment epithelial detachment, is a recognized risk and requires appropriate monitoring.
Yes. Hyperphosphatemia is a characteristic pharmacodynamic effect and is specifically monitored during treatment.
Reported adverse reactions include hyperphosphatemia, diarrhea, stomatitis, dry mouth, nail disorders, palmar-plantar erythrodysesthesia, decreased appetite and skin-related effects.
Astex Pharmaceuticals and Janssen discovered and developed erdafitinib through a collaboration that began in 2008.
BALVERSA is the established branded erdafitinib product described in U.S. and European regulatory information.
The two products should not be described as identical solely because both are identified as containing erdafitinib. Product-specific formulation, manufacturer and authorization information must be established.
Yes. Monitoring can include serum phosphate, eye examinations and assessment of treatment-related adverse effects.
Yes. Erdafitinib is metabolized mainly through CYP2C9 and CYP3A4, so medicines affecting these pathways can alter erdafitinib exposure.
Erdafitinib may cause fetal harm. Pregnancy and reproductive considerations should be reviewed with the treating healthcare professional.
Erdafitinib is a targeted molecular therapy and FGFR tyrosine kinase inhibitor rather than a conventional cytotoxic chemotherapy drug.